RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000131.xml
Synfacts 2009(2): 0119-0119
DOI: 10.1055/s-0028-1087613
DOI: 10.1055/s-0028-1087613
Synthesis of Natural Products and Potential Drugs
© Georg Thieme Verlag
Stuttgart ˙ New York
Synthesis of Telcagepant (MK-0974)
C. S. Burgey*, D. V. Paone, A. W. Shaw, J. Z. Deng, D. N. Nguyen, C. M. Potteiger, S. L. Graham, J. P. Vacca, T. M. Williams
Merck Research Laboratories, West Point, USA
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
22. Januar 2009 (online)

Significance
Telcagepant is a candidate for the treatment of migraine because it antagonizes the calcitonin gene-related peptide (CGRP) receptor. The synthesis depicted (one of two reported) uses a rhodium-catalyzed Hayashi-Miyaura conjugate addition of an arylboronic acid to a nitroolefin as a key step. The synthesis produced multigram quantities of the target for clinical evaluation.